MOMA Therapeutics
MOMA Therapeutics is a clinical-stage biotechnology company developing precision oncology therapies that target highly dynamic proteins, or molecular machines, using its proprietary KNOMATIC™ drug discovery platform integrating structural biology, AI/ML, functional genomics, and CRISPR-based screening.
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What MOMA Therapeutics does
MOMA Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, that develops precision oncology therapeutics by targeting highly dynamic proteins known as molecular machines — proteins that convert chemical energy into process-regulating functions such as protein transport, degradation, DNA unwinding, inflammatory response activation, and cell death. The company's core scientific bet is that this class of proteins, although historically considered undruggable due to their shape-shifting conformations, presents a tractable opportunity if the discovery platform is purpose-built for their dynamics rather than adapted from static-target paradigms.
The company's products and technology are anchored by its proprietary KNOMATIC™ drug discovery platform, which integrates structural biology, functional genomics, high-throughput fragment and DNA-encoded library (DEL) screening, CRISPR-based gene editing, and computational lead optimization supported by machine learning and predictive analytics. MOMA applies KNOMATIC™ to generate a pipeline of precision oncology candidates; its first program entered Phase 1 clinical trials in 2024, with a second lead oncology asset expected to enter the clinic in early 2025. The platform is supported by a knowledge-base / big data infrastructure intended to compound across target programs and by a leadership bench and scientific founders drawn from HHMI, Brandeis, UC Berkeley, and Harvard Medical School.
MOMA is a pre-revenue, privately held company that has raised approximately $236 million across a $86 million Series A (April 2020, led by Third Rock Ventures) and a $150 million Series B (May 2022, led by Goldman Sachs Asset Management) with a 12-investor syndicate. Its customer base in the commercial sense does not yet exist: there are no approved products, no disclosed pricing, and patient access today is limited to clinical trial participation. Revenue mechanics are therefore entirely prospective and contingent on eventual commercialization, licensing, or partnership economics tied to clinical readouts from its oncology pipeline.
MOMA Therapeutics firmographics
Firmographics- Name
- MOMA Therapeutics
- Legal name
- MOMA Therapeutics
- Website
- https://momatx.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- MOMA Therapeutics is a clinical-stage biotechnology company developing precision oncology therapies that target highly dynamic proteins, or molecular machines, using its proprietary KNOMATIC™ drug discovery platform integrating structural biology, AI/ML, functional genomics, and CRISPR-based screening.
- Ownership category
- akta.pro rank
MOMA Therapeutics industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where MOMA Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MOMA Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Marketing channels2 records
MOMA Therapeutics product offering
Product offeringCore offering
MOMA Therapeutics develops precision oncology therapeutics by targeting molecular machines—highly dynamic proteins—using its proprietary KNOMATIC™ discovery platform. The platform integrates cryo-EM structural biology, DNA-encoded library screening, DNA microscopy, fragment-based screening, functional genomics, CRISPR-based validation, and AI/ML-driven lead optimization to identify small-molecule drug candidates against previously undruggable oncology targets, advancing them through preclinical and early clinical development.
Product overview
MOMA Therapeutics is developing a portfolio of precision oncology therapeutics, anchored by its KNOMATIC™ proprietary drug discovery platform. The KNOMATIC™ platform integrates structural biology, functional genomics, high throughput screening (fragment and DEL), CRISPR-based gene editing, and computational lead optimization enabled by machine learning to discover and advance therapeutics targeting highly dynamic proteins. The company's pipeline includes lead oncology programs, with the first program entering Phase 1 clinical trials in 2024 and a second anticipated to enter clinical development in early 2025.
Differentiator
Problem solved
Functional benefit
Brands
- KNOMATIC™: MOMA's proprietary drug discovery platform that integrates structural insights, hit finding technologies, and computational lead optimization to discover therapies targeting highly dynamic proteins.
Products and services
- KNOMATIC™ Drug Discovery Platform KNOMATIC™ is MOMA Therapeutics' proprietary, integrated end-to-end drug discovery platform that combines cryo-EM structural biology, DNA-encoded library (DEL) screening, DNA microscopy, fragment-based screening, functional genomics, CRISPR-based target validation, and AI/ML-driven lead optimization to identify and advance small-molecule precision oncology drug candidates against molecular machine targets. It is the central engine behind all of MOMA's internal oncology programs and is positioned for potential out-licensing and partnership opportunities.
- MOMA Lead Oncology Programs (Precision Oncology Pipeline) MOMA's lead oncology programs are precision small-molecule therapeutics developed using the KNOMATIC™ platform to target highly dynamic protein molecular machines implicated in solid tumor cancers. These programs are progressing through preclinical and early clinical stages with the goal of addressing cancer indications where existing therapies are inadequate or undruggable targets have prevented treatment.
Companies that use MOMA Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
MOMA Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
MOMA Therapeutics partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
MOMA Therapeutics competitors and assessment
Company assessmentDirect peers
- Black Diamond Therapeutics: Precision oncology biotech developing small molecule therapies against previously undruggable or mutation-defined targets, sharing MOMA's focus on novel target classes and computationally enabled discovery.
- Revolution Medicines: Precision oncology company developing targeted inhibitors against difficult-to-drug oncogenic drivers, with comparable clinical-stage pipeline and similar target-class ambitions to MOMA.
- C4 Therapeutics: Clinical-stage company developing targeted protein degraders for oncology, with a comparable platform-driven precision oncology approach to MOMA's undruggable-target focus.
- Foghorn Therapeutics: Clinical-stage oncology company using a proprietary platform to target chromatin regulatory proteins, sharing MOMA's thesis that integrated platform technologies can drug difficult protein classes.
- Arrakis Therapeutics: Biotech focused on drugging RNA targets and other historically undruggable targets through integrated computational and structural biology approaches, comparable to MOMA's platform-driven approach to difficult targets.
- Relay Therapeutics: Clinical-stage precision oncology company applying computational approaches to discover drugs against previously undruggable protein targets, directly comparable to MOMA's KNOMATIC platform strategy of targeting highly dynamic proteins.
Broad incumbents
- Roivant Sciences: Larger biotech holding company that builds and operates multiple platform subsidiaries, with comparable diversified platform-discovery orientation though at greater scale and across broader therapeutic areas than MOMA.
Emerging players
- Schrödinger: Computational drug discovery company combining physics-based modeling with AI/ML to accelerate small molecule discovery, comparable in its platform/compute approach to MOMA's KNOMATIC integration of structural biology and ML.
- Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-throughput biology with machine learning, sharing MOMA's emphasis on AI/ML-driven lead optimization across difficult target classes.
- Neomorph: Early-stage biotech developing targeted protein degraders against difficult-to-drug targets, with overlapping platform philosophy to MOMA's KNOMATIC approach for challenging oncology targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MOMA Therapeutics social profiles
Digital presenceMOMA Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MOMA Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
MOMA Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MOMA Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MOMA Therapeutics
What does MOMA Therapeutics do?
MOMA Therapeutics develops precision oncology therapeutics by targeting molecular machines—highly dynamic proteins—using its proprietary KNOMATIC™ discovery platform. The platform integrates cryo-EM structural biology, DNA-encoded library screening, DNA microscopy, fragment-based screening, functional genomics, CRISPR-based validation, and AI/ML-driven lead optimization to identify small-molecule drug candidates against previously undruggable oncology targets, advancing them through preclinical and early clinical development.
Is MOMA Therapeutics a public or private company?
MOMA Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was MOMA Therapeutics founded?
MOMA Therapeutics was founded in 2020. It employs 101 to 250 people.
Where is MOMA Therapeutics based?
MOMA Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are MOMA Therapeutics's main competitors?
Direct peers on record are Black Diamond Therapeutics, Revolution Medicines, C4 Therapeutics, Foghorn Therapeutics, Arrakis Therapeutics and Relay Therapeutics. Roivant Sciences is listed as a broad incumbent. Emerging players are Schrödinger, Recursion Pharmaceuticals and Neomorph.
Does MOMA Therapeutics have an API?
No public API is recorded for MOMA Therapeutics.
What industry is MOMA Therapeutics in?
MOMA Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.